Sumitomo Pharma sees FY net income 102.00B yen, saw 92.00B yen

Sumitomo Pharma sees FY net income 102.00B yen, saw 92.00B yen

Sumitomo Pharma Raises FY2025 Net Profit Forecast to ¥92 Billion Amid Strong Revenue Growth

Sumitomo Pharma Co. Ltd. (DPM.F) reported robust financial performance in Q2 FY2025, driving a significant upward revision of its full-year net profit forecast. The company now expects net profit of ¥92 billion for FY2025, up from previous guidance, driven by strong revenue growth and strategic business adjustments according to its earnings call.

In Q2 FY2025, revenue rose to ¥227.1 billion, an increase of ¥46.4 billion year-over-year (YoY), with core operating profit reaching ¥96.1 billion. A key contributor to this growth was a non-recurring gain of ¥49 billion from the transfer of its China-Asia business. Additionally, North America revenue surged 56.4% YoY, fueled by demand for key products Orgovyx and Gemtesa.

The company's FY2025 guidance reflects confidence in sustaining this momentum. The revised net profit projection of ¥92 billion underscores improved operational efficiency and the positive impact of strategic divestitures. Sumitomo Pharma's focus on high-growth markets, particularly North America, and its streamlined portfolio following the China-Asia business transfer appear to be critical drivers of profitability.

While the provided materials do not include detailed FY2024 or FY2023 results for comparative analysis, the FY2025 outlook highlights the company's ability to capitalize on market opportunities and optimize its business structure. Investors will likely monitor progress toward this revised target, as well as the long-term implications of its geographic and product strategy.

Data sourced from Sumitomo Pharma's Q2 FY2025 earnings call summary via Yahoo Finance.

Word count: 300